COMP <GO>
BIO vs MRK // ALTMAN Z-SCORE & DEBT/EQUITY
Bio-Rad Laboratories Inc. (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: BIO 4
— MRK 10
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: MRK
LAST: $372.18 (-3.18%) • MKT CAP: $10.28B
balance-sheet
3.59
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
balance-sheet
5.19
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BIO VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BIO | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 51.90% | 74.80% | -22.90 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 0.50% | 20.70% | -20.20 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 60.4x | 15.3x | +45.10 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 3.64% | 3.42% | +0.22 | BIO | /fcf-yield <GO> |
| Operating Margin | 1.80% | 34.30% | -32.50 | MRK | /operating-margins <GO> |
| Net Profit Margin | 29.40% | 28.10% | +1.30 | BIO | /net-margins <GO> |
| Revenue Growth (YoY) | 0.70% | 1.30% | -0.60 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 3.59 | 5.19 | -1.60 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 6.60% | +0.40 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.6 | 56.9 | -5.30 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 0.92 | +0.12 | BIO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 12.6x | 18.4x | -5.80 | BIO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.28B | $361.02B | -$350.74B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BIO REV | MRK REV | BIO GROSS % | MRK GROSS % | BIO FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.58B | $65.01B | 51.9% | 74.8% | $374.6M | $12.36B |
| FY 2024 | $2.57B | $64.17B | 53.7% | 76.3% | $289.6M | $18.10B |
| FY 2023 | $2.67B | $60.12B | 44.0% | 44.0% | $254.7M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BIO // BETA 1.04
MRK // BETA 0.92